Results 141 to 150 of about 58,205 (308)

A Case Report of Promising Response to Combination Therapy With an Immune Checkpoint Inhibitor (Pembrolizumab) and Multi‐Targeted Tyrosine Kinase Inhibitor (Pazopanib) in Metastatic De‐Differentiated Chondrosarcoma

Cancer Reports, Volume 9, Issue 2, February 2026.
ABSTRACT Background We present the case of 72–year‐old male with metastatic de‐differentiated chondrosarcoma (“DDCS”). DDCS is a rare soft tissue cancer that carries a dismal prognosis in the metastatic stage, and is resistant to both traditional chemotherapy and radiotherapy. There is a distinct lack of proven systemic therapies. Case This case report
Matthew Youssef, Peter Grimison
wiley   +1 more source

EXTH-80. IMPAIRED PARP1 DNA REPAIR DEFINES CHEMO-SENSITIVITY IN IDH1-MUTATED CELL [PDF]

, 2018
Yanxin Lu, Yang Liu, Mark R. Gilbert, Jing Wu, Chunzhang Yang   +4 more
openalex   +1 more source

Immunophenotypically Defined Mixed‐Phenotype Acute Leukemias: A Clinicopathologic Analysis of 52 Cases

eJHaem, Volume 7, Issue 1, February 2026.
Abstract Background Immunophenotypically defined mixed‐phenotype acute leukemias (MPAL) are rare and remain a diagnostic and therapeutic dilemma. We aim to explore the clinicopathologic characteristics and oncological outcomes of these entities. Methods A total of 52 patients with immunophenotypically defined MPAL were identified from our pathology ...
Bo Zhang, Olga K Weinberg, Weina Chen, Franklin Fuda, Mingyi Chen, Sharon K. Germans   +5 more
wiley   +1 more source

Clonal Evolution and Lineage Switch from T‐Cell Acute Lymphoblastic Leukemia to Acute Myeloid Leukemia in Therapy‐Resistant PICALM::MLLT10 Leukemia

eJHaem, Volume 7, Issue 1, February 2026.
ABSTRACT Background PICALM::MLLT10‐positive T‐ALL is rare and associated with poor prognosis. Lineage switch to AML is exceptionally uncommon, particularly after long‐term remission. Case Presentation We report an adolescent PICALM::MLLT10‐positive T‐ALL with a cortical thymocyte, non‐ETP phenotype.
Machiko Kawamura, Daichi Sadato, Masayuki Haruta, Nobuko Kubota, Yuka Harada, Takeshi Kobayashi, Noriko Doki, Fumio Kasai, Yu Nishimura, Hirofumi Kobayashi, Nobuo Maseki   +10 more
wiley   +1 more source

Jefferson Digital Commons quarterly report: April-June 2017 [PDF]

, 2016
For Full-Text access download report. Jefferson Digital Commons Quarterly Report: April-June 2017 The Jefferson Digital Commons had another very busy quarter with assets being deposited from across the enterprise.
Copeland, LIBT, James, Duinkerken, MSI, Kelsey, Kipnis, MSI, Daniel G.   +2 more
core   +2 more sources

Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy forIDH1mutant glioma [PDF]

, 2016
Hiroaki Nagashima, Kazuhiro Tanaka, Takashi Sasayama, Yasuhiro Irino, Naoko Sato, Kosei Takeuchi, Katsusuke Kyotani, Akitake Mukasa, Katsu Mizukawa, Junichi Sakata, Yusuke Yamamoto, Kohkichi Hosoda, Tomoo Itoh, Ryohei Sasaki, Eiji Kohmura   +14 more
openalex   +1 more source

Radiogenomics: Current Understandings and Future Perspectives

MedComm, Volume 7, Issue 2, February 2026.
Radiogenomics links imaging phenotypes with genetic variations, offering potential for comprehensive understanding, cost‐effective diagnosis, and prognosis prediction to advance personalized medicine. However, its clinical application remains limited by several challenges.
Xinyu Zhang, Qingpei Lai, Jin Cao, Jerry Chi Fung Ching, Xinzhi Teng, Jiang Zhang, Shara Wee Yee Lee, Ge Ren, Jing Cai   +8 more
wiley   +1 more source

MUTANT IDH1 SUPPRESSES APOPTOSIS REGULATOR PAR-4 IN GLIOMAS [PDF]

, 2014
Craig Horbinski, Yi Liu, M. R. Gilbert, Natasha Kyprianou   +3 more
openalex   +1 more source

Natural Products in Cancer Prevention and Therapy: Current Challenges and Future Directions

MedComm, Volume 7, Issue 2, February 2026.
Natural products play a pivotal role in cancer therapy. They induce cancer cell death by reprogramming four metabolic pathways while precisely targeting the tumor microenvironment and immune cells. These compounds not only leverage novel delivery systems for innovative applications but also demonstrate unique therapeutic efficacy across clinical stages:
Ruimiao Qian, Jun Ge, Ni Fan, Zheng Sun, Chengcheng Zhao, Yujiao Sun, Yingpeng Li, Yunfei Li, Hui Fu   +8 more
wiley   +1 more source

Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents

European Journal of Haematology, Volume 116, Issue 2, Page 160-168, February 2026.
ABSTRACT Acute myeloid leukemia (AML) in elderly patients presents a major therapeutic challenge, as many are deemed unfit for intensive chemotherapy due to age, comorbidities, or frailty. Venetoclax in combination with hypomethylating agents (HMA) has emerged as a standard‐of‐care for this population, yet outcomes remain heterogeneous and predictive ...
Ernesto Vigna, Antonella Bruzzese, Enrica Antonia Martino, Andrea Corsonello, Santino Caserta, Caterina Labanca, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Fortunato Morabito, Massimo Gentile   +11 more
wiley   +1 more source